InflaRx N.V.(IFRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IFRX InflaRx N.V.

交易中 07-29 11:49:38 EDT

1.67

-0.02

-1.48%

最高1.76	最低1.66	成交量25.31万
今开1.69	昨收1.69	日振幅5.98%
总市值2.45亿	流通市值2.14亿	总股本1.47亿
成交额43.11万	换手率0.20%	流通股本1.28亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IFRX","market":"US","secType":"STK","nameCN":"InflaRx N.V.","latestPrice":1.665,"timestamp":1785340119130,"preClose":1.69,"halted":0,"volume":253094,"delay":0,"changeRate":-0.01479289940828397,"floatShares":128448246,"shares":147292900,"eps":-0.711574,"marketStatus":"交易中","change":-0.025,"latestTime":"07-29 11:49:38 EDT","open":1.69,"high":1.761,"low":1.66,"amount":431096.09850420005,"amplitude":0.059763,"askPrice":1.67,"askSize":7376,"bidPrice":1.66,"bidSize":2986,"shortable":3,"etf":0,"ttmEps":-0.711574,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1785355200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1510117200000,"exchange":"NASDAQ","adjPreClose":1.69,"preHourTrading":{"tag":"盘前","latestPrice":1.6848,"preClose":1.69,"latestTime":"09:03 EDT","volume":2640,"amount":4439.415024,"timestamp":1785330232693,"change":-0.0052,"changeRate":-0.003077,"amplitude":0.002781},"postHourTrading":{"tag":"盘后","latestPrice":1.66,"preClose":1.69,"latestTime":"19:58 EDT","volume":336,"amount":562.0946,"timestamp":1785283128869,"change":-0.03,"changeRate":-0.017751,"amplitude":0.017751},"volumeRatio":0.797541,"impliedVol":0.4786,"impliedVolPercentile":0.0677},"requestUrl":"/m/hq/s/IFRX","defaultTab":"news","newsList":[{"id":"1157777626","title":"InflaRx NV提交普通股发行申请 具体规模尚未披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1157777626","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157777626?lang=zh_cn&edition=full","pubTime":"2026-05-07 05:26","pubTimestamp":1778102799,"startTime":"0","endTime":"0","summary":"生物制药公司InflaRx NV已向美国证券交易委员会提交普通股发行申请文件，但本次发行的具体规模及定价条款尚未对外披露。\n根据公开的SEC备案文件显示，此次普通股发行计划已正式启动相关注册程序。市场分析师指出，此类融资活动通常用于支持公司的临床研发项目或扩充营运资金，但最终资金用途仍需以公司官方公告为准。\n作为专注于炎症性疾病创新疗法开发的生物技术企业，InflaRx NV此次资本运作引发业界关注。不过由于备案文件未透露发行规模、定价区间及具体时间表等关键细节，投资者仍需等待后续补充文件披露更多信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180374787","title":"InflaRx坏疽性脓皮病三期数据将亮相2026皮肤科年会 股价盘前异动","url":"https://stock-news.laohu8.com/highlight/detail?id=1180374787","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180374787?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:15","pubTimestamp":1773836113,"startTime":"0","endTime":"0","summary":"InflaRx NV宣布，其候选药物Vilobelimab针对坏疽性脓皮病的三期临床试验结果，将于2026年美国皮肤病学会年会上以\"迟来突破\"口头报告形式公布。该会议定于2026年3月举行。坏疽性脓皮病是一种罕见且严重的嗜中性皮肤病，全球尚无获批疗法。Vilobelimab作为靶向C5a补体蛋白的单克隆抗体，通过抑制炎症通路控制病情，若三期数据积极，有望成为该领域首个靶向疗法。受此消息影响，InflaRx股价在盘前交易中呈现波动。若数据超预期，可能推动股价进一步上行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613147798","title":"Inflarx N.V.盘中异动 急速下挫5.00%报0.850美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613147798","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613147798?lang=zh_cn&edition=full","pubTime":"2026-02-24 01:53","pubTimestamp":1771869235,"startTime":"0","endTime":"0","summary":"北京时间2026年02月24日01时53分，Inflarx N.V.股票出现波动，股价急速跳水5.00%。截至发稿，该股报0.850美元/股，成交量12.1816万股，换手率0.18%，振幅4.84%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.11%。其相关个股中，Arcellx, Inc.、Liminatus Pharma Inc C/Wts 30/04/2030 、Vanda Pharmaceuticals Inc.涨幅较大，Genprex, Inc.、Psyence Biomedical Ltd.、Cardio Diagnostics Holdings Inc.较为活跃，换手率分别为286.54%、222.87%、136.48%，振幅较大的相关个股有Abpro Holdings Inc C/Wts 12/11/2029 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Biovie Inc C/Wts 08/08/2030，振幅分别为70.43%、66.80%、36.63%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224015355a7169930&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260224015355a7169930&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609465653","title":"Inflarx N.V.盘中异动 股价大涨6.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609465653","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609465653?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:36","pubTimestamp":1770215810,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日22时36分，Inflarx N.V.股票出现异动，股价大幅拉升6.82%。截至发稿，该股报0.940美元/股，成交量1.0609万股，换手率0.02%，振幅0.12%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.80%。其相关个股中，Celularity Inc C/Wts 16/07/2026 、Liminatus Pharma, Inc.、Oncolytics Biotech Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Gri Bio, Inc.、Evogene Ltd.较为活跃，换手率分别为355.16%、188.51%、99.10%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Liminatus Pharma, Inc.、Liminatus Pharma Inc C/Wts 30/04/2030 ，振幅分别为61.25%、28.97%、18.20%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204223650a47c54bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204223650a47c54bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608876752","title":"Inflarx N.V.盘中异动 早盘股价大涨5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608876752","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608876752?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:30","pubTimestamp":1770042635,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日22时30分，Inflarx N.V.股票出现异动，股价急速拉升5.46%。截至发稿，该股报0.930美元/股，成交量6734股，换手率0.01%，振幅0.00%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Polyrizon Ltd.、Molecular Partners Ag涨幅较大，60 Degrees Pharmaceuticals, Inc.、Vyome Holdings, Inc.、Vivosim Labs, Inc.较为活跃，换手率分别为246.67%、14.85%、14.42%，振幅较大的相关个股有Context Therapeutics Inc.、Inflarx N.V.、Estrella Immunopharma, Inc.，振幅分别为6.51%、5.70%、5.27%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202223035a473bb90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202223035a473bb90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517399165","title":"Inflarx N.V.盘中异动 早盘股价大涨6.80%报1.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517399165","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517399165?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:35","pubTimestamp":1741271711,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时35分，Inflarx N.V.股票出现异动，股价大幅拉升6.80%。截至发稿，该股报1.34美元/股，成交量9036股，换手率0.01%，振幅2.41%。Inflarx N.V.股票所在的生物技术行业中，整体跌幅为0.62%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223511abeb78af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223511abeb78af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517607554","title":"Inflarx N.V.盘中异动 快速下挫5.60%报1.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517607554","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517607554?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:52","pubTimestamp":1741110762,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日01时52分，Inflarx N.V.股票出现异动，股价快速下跌5.60%。截至发稿，该股报1.18美元/股，成交量20.7216万股，换手率0.31%，振幅8.40%。Inflarx N.V.股票所在的生物技术行业中，整体跌幅为0.21%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015242989bdd22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305015242989bdd22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516659884","title":"Inflarx N.V.盘中异动 股价大跌5.04%报1.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516659884","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516659884?lang=zh_cn&edition=full","pubTime":"2025-03-04 01:15","pubTimestamp":1741022138,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日01时15分，Inflarx N.V.股票出现波动，股价大幅下跌5.04%。截至发稿，该股报1.32美元/股，成交量16.6346万股，换手率0.25%，振幅7.91%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.16%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304011538a25d7095&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304011538a25d7095&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514334750","title":"Inflarx N.V.盘中异动 下午盘快速下跌5.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514334750","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514334750?lang=zh_cn&edition=full","pubTime":"2025-02-28 03:53","pubTimestamp":1740686039,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日03时53分，Inflarx N.V.股票出现波动，股价大幅下挫5.67%。Inflarx N.V.股票所在的生物技术行业中，整体跌幅为0.19%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280353599632ec2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502280353599632ec2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514090025","title":"Inflarx N.V.盘中异动 股价大跌5.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090025","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514090025?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:36","pubTimestamp":1740494191,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时36分，Inflarx N.V.股票出现波动，股价急速跳水5.63%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.25%。其相关个股中，Moleculin Biotech, Inc.、Gt Biopharma, Inc.、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为783.50%、493.57%、265.19%，振幅较大的相关个股有Gt Biopharma, Inc.、Adial Pharmaceuticals, Inc、Dominari Holdings Inc.，振幅分别为23.15%、20.51%、16.35%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223631962ff3c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223631962ff3c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514777994","title":"Inflarx N.V.盘中异动 临近午盘股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514777994","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514777994?lang=zh_cn&edition=full","pubTime":"2025-02-25 00:52","pubTimestamp":1740415958,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日00时52分，Inflarx N.V.股票出现波动，股价大幅下跌5.19%。截至发稿，该股报1.74美元/股，成交量14.3972万股，换手率0.21%，振幅4.37%。Inflarx N.V.股票所在的生物技术行业中，整体跌幅为0.13%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225005238abdb2d5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225005238abdb2d5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512161823","title":"Inflarx N.V.盘中异动 早盘急速下挫5.00%报1.90美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512161823","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512161823?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:29","pubTimestamp":1739892597,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时29分，Inflarx N.V.股票出现波动，股价大幅下跌5.00%。截至发稿，该股报1.90美元/股，成交量14.5423万股，换手率0.25%，振幅5.00%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.66%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232957abd3bcc2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232957abd3bcc2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511569938","title":"Inflarx N.V.股价重挫22.96% 市值跌2812.07万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511569938","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511569938?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:32","pubTimestamp":1739543523,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时32分，Inflarx N.V.股票出现波动，股价急速下跌22.96%。截至发稿，该股报2.08美元/股，成交量32.6304万股，换手率0.55%，振幅3.33%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.24%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223203abcf0688&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214223203abcf0688&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IFRX","VRPX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511457308","title":"Inflarx N.V.盘中异动 下午盘股价大涨5.84%报2.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511457308","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511457308?lang=zh_cn&edition=full","pubTime":"2025-02-14 02:04","pubTimestamp":1739469849,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日02时04分，Inflarx N.V.股票出现异动，股价快速拉升5.84%。截至发稿，该股报2.72美元/股，成交量13.5615万股，换手率0.23%，振幅7.59%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.83%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140204109621e58d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140204109621e58d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510387479","title":"Inflarx N.V.盘中异动 股价大跌5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510387479","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510387479?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:37","pubTimestamp":1739284629,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时37分，Inflarx N.V.股票出现波动，股价急速下跌5.38%。截至发稿，该股报2.46美元/股，成交量1.8941万股，换手率0.03%，振幅2.69%。Inflarx N.V.股票所在的生物技术行业中，整体跌幅为0.91%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223710961f48bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211223710961f48bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OCEA","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510977358","title":"Inflarx N.V.盘中异动 股价大涨5.26%报2.60美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510977358","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510977358?lang=zh_cn&edition=full","pubTime":"2025-02-11 04:54","pubTimestamp":1739220855,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日04时54分，Inflarx N.V.股票出现波动，股价急速拉升5.26%。截至发稿，该股报2.60美元/股，成交量28.1854万股，换手率0.48%，振幅7.89%。Inflarx N.V.股票所在的生物技术行业中，整体跌幅为0.98%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211045416961e46c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211045416961e46c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508457757","title":"Inflarx N.V.盘中异动 快速下跌8.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508457757","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508457757?lang=zh_cn&edition=full","pubTime":"2025-02-04 22:38","pubTimestamp":1738679891,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日22时38分，Inflarx N.V.股票出现波动，股价大幅下跌8.30%。截至发稿，该股报2.21美元/股，成交量4042股，换手率0.01%，振幅0.83%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.10%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502042238119617d8cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502042238119617d8cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507978677","title":"Inflarx N.V.盘中异动 下午盘股价大涨5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507978677","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507978677?lang=zh_cn&edition=full","pubTime":"2025-01-31 03:58","pubTimestamp":1738267100,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日03时58分，Inflarx N.V.股票出现波动，股价快速上涨5.80%。截至发稿，该股报2.37美元/股，成交量14.2841万股，换手率0.24%，振幅6.70%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.22%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131035821a2348bce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131035821a2348bce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507510029","title":"Inflarx N.V.盘中异动 急速拉升5.26%报2.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507510029","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507510029?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:55","pubTimestamp":1738076140,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日22时55分，Inflarx N.V.股票出现异动，股价快速上涨5.26%。截至发稿，该股报2.40美元/股，成交量1.1804万股，换手率0.02%，振幅3.95%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为0.02%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128225540abbb6b55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128225540abbb6b55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506305538","title":"Inflarx N.V.盘中异动 早盘急速拉升5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506305538","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506305538?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:44","pubTimestamp":1737989065,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时44分，Inflarx N.V.股票出现异动，股价快速上涨5.56%。截至发稿，该股报2.47美元/股，成交量2.0259万股，换手率0.03%，振幅5.56%。Inflarx N.V.股票所在的生物技术行业中，整体涨幅为1.00%。Inflarx N.V.公司简介：InflaRx NV是一家临床生物制药公司，致力于应用专有的抗 C5a 技术来发现和开发称为 C5a 的补体激活因子的特异性抑制剂。它还在开发 IFX-1 来治疗 AAV，这是一种威胁生命的自身免疫性疾病，与严重的炎症发作相关，会损害肾功能并导致致命的器官功能障碍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127224425a2316dab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127224425a2316dab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inflarx.com","stockEarnings":[{"period":"1week","weight":-0.0663},{"period":"1month","weight":-0.1198},{"period":"3month","weight":-0.1465},{"period":"6month","weight":0.8316},{"period":"1year","weight":0.9272},{"period":"ytd","weight":0.6733}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":0.0163},{"period":"3month","weight":0.0411},{"period":"6month","weight":0.0675},{"period":"1year","weight":0.1632},{"period":"ytd","weight":0.0864}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"InflaRx N.V.于2017年6月根据荷兰法律成立，根据公司重组的条款，该公司是一家InflaRx GmbH的控股的公司。该公司是一家临床阶段的生物制药公司，专注于应用其独有的反C5a技术来发现和开发一种名为C5a的补充激活因子的一级、有效和特异性抑制剂。C5a是一种强大的炎症介质，涉及多种自身免疫和其他炎症疾病的进展。","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":-0.087223},{"month":2,"riseRate":0.555556,"avgChangeRate":-0.037253},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.085832},{"month":4,"riseRate":0.666667,"avgChangeRate":0.522973},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.079812},{"month":6,"riseRate":0.222222,"avgChangeRate":-0.162391},{"month":7,"riseRate":0.333333,"avgChangeRate":0.050141},{"month":8,"riseRate":0.375,"avgChangeRate":0.063387},{"month":9,"riseRate":0.375,"avgChangeRate":-0.049481},{"month":10,"riseRate":0.5,"avgChangeRate":0.024934},{"month":11,"riseRate":0.5,"avgChangeRate":0.08777},{"month":12,"riseRate":0.666667,"avgChangeRate":0.08515}],"exchange":"NASDAQ","name":"InflaRx N.V.","nameEN":"InflaRx N.V."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"InflaRx N.V.(IFRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供InflaRx N.V.(IFRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"InflaRx N.V.,IFRX,InflaRx N.V.股票,InflaRx N.V.股票老虎,InflaRx N.V.股票老虎国际,InflaRx N.V.行情,InflaRx N.V.股票行情,InflaRx N.V.股价,InflaRx N.V.股市,InflaRx N.V.股票价格,InflaRx N.V.股票交易,InflaRx N.V.股票购买,InflaRx N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"InflaRx N.V.(IFRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供InflaRx N.V.(IFRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}